Clinical trials: Monotherapy After PCI
Monotherapy After PCI
Acetyl Salicylic Elimination Trial: The ASET Pilot Study
A multicenter, single arm, open-label trial of prasugrel monotherapy after PCI with the new-generation thin-strut biodegradable polymer everolimus-eluting SYNERGY® stent in patients with chronic stable angina
- Trial name
- ASET (NCT03469856)
- Testing
- Prasugrel monotherapy
- Where
- Brazil
- Volunteers
- 200 people
- Sponsor
- Pedro A. Lemos
Atrial Fibrillation, Coronary Artery Disease
Rivaroxaban Monotherapy After CYP2C19 Genotype Testing in Patients With Atrial Fibrillation and Percutaneous Coronary Intervention
Rationale: Patients with atrial fibrillation who undergo percutaneous coronary intervention for coronary artery disease are treated with antiplatelet therapy on top of a non-vitamin K oral anticoagulant.
- Trial name
- IMPACT AF-PCI (NCT06103266)
- Testing
- Rivaroxaban
- Volunteers
- 50 people
- Sponsor
- J.P.S Henriques
Coronary Artery Disease
SMart Angioplasty Research Team: CHoice of Optimal Anti-Thrombotic Strategy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents 3
This study is a prospective, open-label, two-arm, randomized multicenter trial to compare the efficacy and safety of clopidogrel versus aspirin monotherapy beyond the standard duration of dual antiplatelet therapy (DAPT) (more…
- Trial name
- SMART-CHOICE3 (NCT04418479)
- Testing
- Aspirin, Clopidogrel
- Where
- South Korea
- Volunteers
- 5,506 people
- Sponsor
- Joo-Yong Hahn
Coronary Artery Disease, Percutaneous Coronary Intervention
Study of the Long-term Effects of P2Y12 Inhibitor Monotherapy and Coagulation Markers After Percutaneous Coronary Angioplasty.
Patients who undergo percutaneous coronary intervention (PCI) are commonly treated with antiplatelet therapy to prevent stent thrombosis and recurrence of events.
- Conditions
- Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndromes, Antiplatelet Therapy
- Trial name
- HI-TECH 2 (NCT07582835)
- Testing
- Clopidogrel, Ticagrelor, Prasugrel
- Where
- Switzerland
- Volunteers
- 355 people
- Sponsor
- Cardiocentro Ticino
Coronary Heart Disease
Pharmacodynamic and Short-term Effects of Half-dose Ticagrelor With or Without Aspirin vs DAPT From Day of PCI in CCS
Six months of aspirin plus clopidogrel remains the recommended antiplatelet regimen after percutaneous coronary intervention (PCI) for chronic coronary syndrome (CCS), with the more potent P2Y₁₂ inhibitors reserved for the acute…
- Trial name
- NCT07622056
- Testing
- Aspirin 100 mg + clopidogrel (300 mg load → 75 mg daily) ×6 months, then aspirin monotherapy, Aspirin 100 mg + ticagrelor (90 mg load → 45 mg twice daily) ×6 months, then aspirin monotherapy, Ticagrelor (90 mg load → 45 mg twice daily) monotherapy; aspirin stopped at day 2 after randomisation; continued indefinitely
- Where
- Taiwan
- Volunteers
- 54 people
- Sponsor
- Kaohsiung Veterans General Hospital.
Coronary Artery Disease, DES
A Randomized Comparison of CLOpidogrel Monotherapy Versus Extended Dual-antiplatelet Therapy Beyond 12 Months After Implantation of Drug-eluting StEnts in High-risk Lesions or Patients; A-CLOSE Trial
We hypothesized that clopidogrel mono-therapy will not be inferior to the extended DAPT in terms of the occurrence of both ischemic and bleeding events, for lesions or patients at high risk for either ischemic or bleeding…
- Trial name
- NCT03947229
- Testing
- Clopidogrel mono-therapy, Dual-antiplatelet therapy
- Where
- South Korea
- Volunteers
- 3,200 people
- Sponsor
- Yonsei University
Bleeding Complications
Clopidogrel Monotherapy in Patients With High Bleeding Risk
The goal of this research is to show that a shorter duration of two antiplatelet medications (compared to the standard of care) is safe and effective while reducing the risk of bleeding complications.
- Trial name
- NCT05223335
- Testing
- Clopidogrel, Prasugrel, Tricagrelor
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- Mayo Clinic
Coronary Artery Disease Requiring Coronary Revascularization With Newer Generation DES Implantation
Effect of High-intensity Statin With Ezetimibe COmbination theRapy Versus High-intensity sTatin Monotherapy After Percutaneous Coronary Intervention With Drug-eluting Stents; the ESCORT Trial
This study sought to evaluate whether ezetimibe combination to high-intensity statin therapy will have more prominent beneficial effect compared to high-intensity statin monotherapy in patients who underwent coronary…
- Trial name
- NCT05782777
- Testing
- ezetimibe/high-intensity statin combination therapy (ezetimibe 10mg plus atoravastatin 40mg), high-intensity statin monotherapy (atoravastatin 40mg)
- Where
- South Korea
- Volunteers
- 4,310 people
- Sponsor
- Yonsei University
Coronary Artery Disease
The PIONEER-IV Study is Comparing Clinical Outcomes Between Angiography-derived Physiology Guidance to Usual Care in an All-comers PCI Population With Unrestrictive Use of the HT Supreme Sirolimus-eluting Stent
PIONEER-IV is a prospective, single-blind (patient), randomized, 1:1, controlled, multi-center study comparing clinical outcomes between angiography-derived physiology guidance to LRDP and usual care in an all-comers patient…
- Trial name
- PIONEER-IV (NCT04923191)
- Testing
- Angiography-derived physiology guidance/Local routine diagnostic procedure (LRDP) and usual care
- Where
- 19 sites in Belgium, Ireland and 3 more
- Volunteers
- 2,540 people
- Sponsor
- National University of Ireland, Galway, Ireland
Acute Coronary Syndrome, Percutaneous Coronary Intervention
Sequential MonotherApy of TicagrElor and Clopidogrel After Coronary Intervention
The MATE study is a randomized, multicenter, open-label, investigator-initiated clinical trial aimed to evaluate efficacy and safety of sequential monotherapy of ticagrelor and clopidogrel in patients with acute coronary syndrome…
- Trial name
- MATE (NCT04937699)
- Testing
- Standard-DAPT of Ticagrelor plus aspirin, Sequential monotherapy of Ticagrelor and clopidogrel
- Where
- China
- Volunteers
- 2,690 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Coronary Arterial Disease (CAD), Percutaneous Coronary Intervention (PCI)
Prasugrel Monotherapy Reduced Dose in Acute and Chronic Coronary Syndrome Patients After Percutaneous Coronary Intervention (PROMOTE)
Rationale: Dual antiplatelet therapy, consisting of aspirin and a P2Y12-inhibitor, reduces the risk of stent-related and non-stent-related ischemic events after percutaneous coronary intervention (PCI).
- Trial name
- PROMOTE (NCT06916520)
- Testing
- Prasugrel 5 mg, Dual Antiplatelet (DAPT) Therapy
- Where
- Netherlands
- Volunteers
- 300 people
- Sponsor
- J.P.S Henriques
Coronary Artery Disease
Ticagrelore Alone Post PCI
After PCI for CCS patients, single center double blind randomization will be done and patients will receive aspirin 80 mg and clopidogrel 75 mg versus 90 mg two times daily of ticagrelor, for 6 months and MACE will be followed in…
- Trial name
- TICALONE (NCT06509893)
- Testing
- aspirin 80 mg and clopidogrel 75 mg daily, Ticagrelor 90 MG
- Where
- 2 sites in Iran
- Volunteers
- 5,400 people
- Sponsor
- Shiraz University of Medical Sciences
Coronary Artery Disease
A Study to Evaluate the Impact of 11-month Ticagrelor Monotherapy Following One-month DAPT After PCI
PIONEER IV CHINA is sought to investigate the safety and efficacy of 11-month ticagrelor monotherapy following one-month dual antiplatelet therapy (DAPT) after HT Supreme drug-eluting stent system at 12 months follow-up.
- Trial name
- NCT05015699
- Testing
- HT Supreme
- Sponsor
- Sino Medical Sciences Technology Inc.
ST Elevation Myocardial Infarction
Safety of Ticagrelor Monotherapy After Primary Percutaneous Coronary Intervention for ST-elevation Myocardial Infarction and the Effect on Intramyocardial Haemorrhage
The main goal of this clinical trial is to assess whether direct omission of aspirin after Percutaneous Coronary Intervention (PCI) with the continuation of ticagrelor monotherapy for 12 months versus 12 months ticagrelor plus…
- Trial name
- STOP-IMH (NCT05986968)
- Testing
- Ticagrelor, Aspirin
- Where
- 5 sites in Netherlands
- Volunteers
- 200 people
- Sponsor
- Radboud University Medical Center
ST-segment Elevation Myocardial Infarction (STEMI)
Bivalirudin with Prolonged Infusion During PCI Versus Heparin After Fibrinolytic Therapy
This multicenter, randomized controlled trial in China aims to enroll 2,400 patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (PCI) within 24 hours post-fibrinolysis.
- Trial name
- BRIGHT-FIT (NCT06861374)
- Testing
- Bivalirudin, Unfractionated heparin
- Volunteers
- 2,400 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Chronic Coronary Syndrome, Non ST Segment Elevation Acute Coronary Syndrome
Acetyl Salicylic Elimination Trial JAPAN: The ASET JAPAN Pilot Study
The ASET Japan Pilot study is a multicenter, single arm, open-label trial of single antiplatelet therapy with prasugrel for patients undergoing successful and optimal Percutaneous Coronary Intervention (PCI) for Chronic Coronary…
- Trial name
- ASET-JAPAN (NCT05117866)
- Testing
- prasugrel Monotherapy
- Where
- 13 sites in Ireland, Japan
- Volunteers
- 307 people
- Sponsor
- Meditrix Corp
ST-segment Elevation Myocardial Infarction (STEMI)
PRasugrEl Monotherapy Following prImary percUtaneous Coronary Intervention for ST-elevation Myocardial Infarction
The aim of this study is to evaluate the safety of prasugrel monotherapy without aspirin versus 12-month dual antiplatelet therapy (DAPT) in patients with STEMI using platinum-chrome everolimus-eluting stent (PtCr-EES: SYNERGYTM).
- Trial name
- PREMIUM (NCT05709626)
- Testing
- No aspirin (Prasugurel monotherapy), 12-month DAPT
- Where
- Japan
- Volunteers
- 2,258 people
- Sponsor
- Kindai University